20/20 Biolabs, Inc.(AIDX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $2.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
AIDX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for 20/20 Biolabs, Inc. (AIDX), a Technology sector company. AIDX is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $2.0m in revenue. Based on the latest XBRL financial filings (Q1 2026), 20/20 Biolabs, Inc. reports quarterly revenue of $353.4K, net income of $-2.2M, free cash flow of $-1.3M. Top institutional holders of AIDX by reported 13-F value include Cresset Asset Management,, CITADEL ADVISORS, XTX Topco Ltd, based on the most recent SEC filings. AIDX trades on the Nasdaq exchange and files with the SEC under CIK 1139685. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AIDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for 20/20 Biolabs, Inc. directly from SEC EDGAR.
Revenue
Q1 2026
$353.4K
Net Income
Q1 2026
$-2.2M
Free Cash Flow
Q1 2026
$-1.3M
ROIC
Q1 2026
-56.5%
AI Insight: AIDX Financial Trends
Pre-revenue biotech with minimal operating activity and negative equity position limits meaningful trend analysis.
• Q1 2026 shows $0M revenue with $-2M net loss and $-1M operating loss, typical early-stage biotech burn.
⚠ Equity turned negative ($-0M in Q4 2025 to $3M in Q1 2026); balance sheet fragility requires funding visibility.
⚠ Operating cash flow negative at $-1M; runway and path to revenue remain unclear from available data.
AI Insight: AIDX Ratio Trends
Insufficient data: no financial metrics available for Q4 2025 or Q1 2026.
• All ratio fields (OpMargin, NPM, ROE, ROA, ROIC, D/E) are blank across both periods.
⚠ Cannot assess profitability, returns, or leverage trends without reported data.
Get alerted when AIDX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for 20/20 Biolabs, Inc. including:
Top Institutional Holders of AIDX
Cresset Asset Management, LLC
$497.0K264,368 shCITADEL ADVISORS LLC
$30.5K16,227 shXTX Topco Ltd
$19.4K10,329 shUBS Group AG
$15.6K8,314 shMAI Capital Management
$1.9K1,000 shTOTH FINANCIAL ADVISORY CORP
$296.00157 shAllworth Financial LP
$57.0030 sh
| Fund | Value | Shares |
|---|---|---|
| Cresset Asset Management, LLC | $497.0K | 264,368 |
| CITADEL ADVISORS LLC | $30.5K | 16,227 |
| XTX Topco Ltd | $19.4K | 10,329 |
| UBS Group AG | $15.6K | 8,314 |
| MAI Capital Management | $1.9K | 1,000 |
| TOTH FINANCIAL ADVISORY CORP | $296.00 | 157 |
| Allworth Financial LP | $57.00 | 30 |
More Technology Companies
View all Technology →Put AIDX on your watchlist
Track score changes the day 20/20 Biolabs, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is AIDX a good stock to buy?
13F Pro's AI-powered analysis of 20/20 Biolabs, Inc. (AIDX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Technology sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AIDX are available on the AIDX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own AIDX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AIDX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of 20/20 Biolabs, Inc.'s investment landscape.